{'fraction_non_alphanumeric': 0.01353637901861252, 'fraction_numerical': 0.0, 'mean_word_length': 5.7272727272727275, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Re: Community Treatment Orders for Psychiatric Patients: The Emperor with No Clothes

It is an unfortunate consequence of the current pharmacoeconomic climate—and the limited remaining duration of patent protection for OXC—that adequately powered clinical trials to definitively assess its safety and efficacy are unlikely to be carried out. We feel that patients with BD refractory to standard therapies will benefit from the availability of other treatment options. In this light, we believe that our clinical recommendations are appropriately cautious and justified by the available data: